0.4520
-0.0095
(-2.06%)
At close: January 10 at 4:00:02 PM EST
0.4399
-0.01
(-2.68%)
After hours: 7:59:49 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | -- | 1 | 1 |
| Avg. Estimate | -0.31 | 0 | -1.49 | 0.18 |
| Low Estimate | -0.42 | 0 | -1.49 | 0.18 |
| High Estimate | -0.21 | 0 | -1.49 | 0.18 |
| Year Ago EPS | -0.67 | -- | -1.81 | -1.49 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 1 | 4 | 4 |
| Avg. Estimate | 13.87M | 22M | 25.91M | 142.31M |
| Low Estimate | 10M | 22M | 21.56M | 41.68M |
| High Estimate | 17M | 22M | 28.6M | 232.3M |
| Year Ago Sales | -- | -- | -- | 25.91M |
| Sales Growth (year/est) | 0.00% | 0.00% | 0.00% | 449.27% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.47 | -0.39 | -0.39 | -0.35 |
| EPS Actual | -0.67 | -0.38 | -0.4 | -0.51 |
| Difference | -0.2 | 0.01 | -0.01 | -0.16 |
| Surprise % | -42.55% | 2.56% | -2.56% | -45.71% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.31 | 0 | -1.49 | 0.18 |
| 7 Days Ago | -0.31 | 0 | -1.49 | 0.18 |
| 30 Days Ago | -0.31 | 0 | -1.49 | -0.13 |
| 60 Days Ago | -0.05 | 0 | -1.17 | -0.14 |
| 90 Days Ago | 0.12 | 0 | -0.99 | -0.44 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | 1 | 1 |
| Up Last 30 Days | -- | -- | -- | 1 |
| Down Last 7 Days | 1 | -- | -- | -- |
| Down Last 30 Days | 1 | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| IVVD | 52.99% | -- | 17.68% | 112.08% |
| S&P 500 | 8.66% | 11.51% | 14.05% | 13.39% |
Upgrades & Downgrades
| Maintains | D. Boral Capital: Buy to Buy | 1/10/2025 |
| Maintains | D. Boral Capital: Buy to Buy | 11/21/2024 |
| Maintains | Morgan Stanley: Overweight to Overweight | 11/20/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 11/20/2024 |
| Maintains | D. Boral Capital: Buy to Buy | 11/14/2024 |
| Initiated | EF Hutton: Buy | 10/30/2024 |
Related Tickers
NBY NovaBay Pharmaceuticals, Inc.
0.6970
+9.16%
ELEV Elevation Oncology, Inc.
0.6504
-13.72%
GDTC CytoMed Therapeutics Limited
2.7600
+20.52%
SNSE Sensei Biotherapeutics, Inc.
0.5125
-3.30%
UNCY Unicycive Therapeutics, Inc.
0.6644
-10.81%
INAB IN8bio, Inc.
0.3233
+3.42%
NLSP NLS Pharmaceutics AG
2.3200
-3.73%
DTIL Precision BioSciences, Inc.
5.70
+26.67%
CYCC Cyclacel Pharmaceuticals, Inc.
0.4199
+1.21%
CDT Conduit Pharmaceuticals Inc.
0.1233
+50.37%